TAK-831 Placebo

DRUG2 trials

Sponsors

Neurocrine Biosciences

Conditions

Friedreich AtaxiaSchizophrenia, Cerebellar Ataxia

Phase 1

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

TerminatedNCT02566759

Neurocrine BiosciencesSchizophrenia, Cerebellar Ataxia

Start: 2015-09-23End: 2016-07-12Updated: 2021-06-14

Phase 2

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

CompletedNCT03214588

Neurocrine BiosciencesFriedreich Ataxia

Start: 2017-11-08End: 2018-12-27Updated: 2021-06-14